303 related articles for article (PubMed ID: 37667341)
1.
Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
[TBL] [Abstract][Full Text] [Related]
2. The use of
Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S
Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
[TBL] [Abstract][Full Text] [Related]
3. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5.
Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
[TBL] [Abstract][Full Text] [Related]
6. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of
Guo S; Zhou C; Zhang Y; Wang D; Niu T; Zhou F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1812-1819. PubMed ID: 38448374
[TBL] [Abstract][Full Text] [Related]
8. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
9. The PRIMARY Score: Using Intraprostatic
Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS
J Nucl Med; 2022 Nov; 63(11):1644-1650. PubMed ID: 35301240
[TBL] [Abstract][Full Text] [Related]
10. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38281891
[TBL] [Abstract][Full Text] [Related]
11. Prediction of clinically significant prostate cancer using a novel
Cheng C; Liu J; Yi X; Yin H; Qiu D; Zhang J; Chen J; Hu J; Li H; Li M; Zu X; Tang Y; Gao X; Hu S; Cai Y
Transl Androl Urol; 2023 Jul; 12(7):1115-1126. PubMed ID: 37554522
[TBL] [Abstract][Full Text] [Related]
12. Multiparametric Magnetic Resonance Imaging,
Kubihal V; Sharma S; Kumar R; Seth A; Kumar R; Kaushal S; Sarangi J; Gupta R; Das CJ
Indian J Nucl Med; 2021; 36(4):362-370. PubMed ID: 35125753
[TBL] [Abstract][Full Text] [Related]
13.
Zhang LL; Li WC; Xu Z; Jiang N; Zang SM; Xu LW; Huang WB; Wang F; Sun HB
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):483-492. PubMed ID: 32734457
[TBL] [Abstract][Full Text] [Related]
14. Targeted Biopsy in Men High Risk for Prostate Cancer:
Pepe P; Pennisi M
Clin Genitourin Cancer; 2023 Dec; 21(6):639-642. PubMed ID: 37394379
[TBL] [Abstract][Full Text] [Related]
15. Combined Utility of
Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
[TBL] [Abstract][Full Text] [Related]
16. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
[No Abstract] [Full Text] [Related]
17. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
[TBL] [Abstract][Full Text] [Related]
18. Detection Rate of
Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of
Zhang J; Shao S; Wu P; Liu D; Yang B; Han D; Li Y; Lin X; Song W; Cao M; Zhang J; Kang F; Qin W; Wang J
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):908-920. PubMed ID: 30635755
[TBL] [Abstract][Full Text] [Related]
20. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer.
Pepe P; Pepe L; Tamburo M; Marletta G; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2022 Sep; 94(3):274-277. PubMed ID: 36165469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]